Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies Please visit their website for more information.
*Proprietary Buy Sell Volume Indicator
| Revenue: $0M |
| Revenue Growth (YOY): nan% |
| Profit (% of Rev): nan% |
| Income (% of Rev): -inf% |
| Income Growth (YOY): 86.22% |
| Operating Income: $-33M |
| Operating Cash Flow: $-20M |
| Operating Cash Flow Growth (YoY): 61.24% |
| Annual Dividend Yield: 0.00% |
| Total Assets: $204M |
| Total Liabilities: $30M |
| Cash & Equivalent: $171M |
| Total Debt: $15M |
| Debt/Equity: 0.09 |
| Quick Ratio: 8.11 |
| Current Ratio: 8.11 |
| Price/Book: 1.33 |
| Price/Earnings: -1.89 |
| EBITDA: $-33M |
| EPS: -0.63 |
Our proprietary analysis employs a weighted average approach integrating both functional and technical parameters, tailored to the sector, industry, and microeconomic factors. This methodology assigns dynamic weights to the parameters, with a focus on recent trends, ensuring a nuanced evaluation for informed investment decisions. Considering all the above parameters, in addition to some of the derived parameters of the stock in conjunction with its sector and macroeconomic conditions, our proprietary Weighted Average AI model gives a rank of Sell.
TheoryofStocks is not registered as an investment advisor with any regulatory authority. The information provided on this Website is for educational purposes only and should not be construed as financial or investment advice. By continuing to use this site, you are agreeing to the Terms of Use and Privacy Policy. Please read our Disclaimer.
Contact @ support@theoryofstocks.com
© 2024 Stock Articles. All rights reserved.